<button id="eiezk"><video id="eiezk"></video></button>

產品名稱

BMS 833923 - XL 139

產品貨號

Axon 2356 CAS [1059734-66-5] MF C30H27N5OMW 473.57 Purity: 99% Soluble in DMSO Description Oral, small molecule antagonist of the Hedgehog (Hh) signaling component Smoothened (SMO). Treatment with BMS 833923 leads to a decreased expression of GLI1 and PTCH1 in EGI-1 cells, reduced tumor growth in vitro, and a prolongation of survival in vivo in different human cancers. Additionally, SMO inhibition by BMS 833923 leads to decreased proliferation and induces apoptosis in esophageal adenocarcinoma cells (EACs). References Certificates Categories Extra info T.L. Lin et al. Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco. Targets Ther. 2012, 5, 47-58. ? J. Brechbiel et al. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat. Rev. 2014, 40, 750-759. ? D. Riedlinger et al. Hedgehog pathway as a potential treatment target in human cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 2014, 21, 607-615. ? A.H. Zaidi et al. Smoothened inhibition leads to decreased proliferation and induces apoptosis in esophageal adenocarcinoma cells. Cancer Invest. 2013, 31, 480-489. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology CNS Stem Cell Smoothened (SMO) Hedgehog F Oral antagonist of the Hedgehog signaling component Smoothened (SMO) Chemical name N-(2-methyl-5-((methylamino)methyl)phenyl)-4-(4-phenylquinazolin-2-ylamino)benzamide Parent CAS No. [1059734-66-5] Order Size Unit Price Stock 5 mg €75.00 In Stock

產品價格

現貨詢價，電話：010-67529703

產品規(guī)格

產品品牌

axonmedchem

產品概述

產品詳情

BMS 833923 - XL 139

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 2356

CAS [1059734-66-5]

MF C30H27N5O
MW 473.57

Purity: 99%
Soluble in DMSO

BMS 833923

Description

Oral, small molecule antagonist of the Hedgehog (Hh) signaling component Smoothened (SMO). Treatment with BMS 833923 leads to a decreased expression of GLI1 and PTCH1 in EGI-1 cells, reduced tumor growth in vitro, and a prolongation of survival in vivo in different human cancers. Additionally, SMO inhibition by BMS 833923 leads to decreased proliferation and induces apoptosis in esophageal adenocarcinoma cells (EACs).

T.L. Lin et al. Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco. Targets Ther. 2012, 5, 47-58.

J. Brechbiel et al. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat. Rev. 2014, 40, 750-759.

D. Riedlinger et al. Hedgehog pathway as a potential treatment target in human cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 2014, 21, 607-615.

A.H. Zaidi et al. Smoothened inhibition leads to decreased proliferation and induces apoptosis in esophageal adenocarcinoma cells. Cancer Invest. 2013, 31, 480-489.

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology CNS Stem Cell Smoothened (SMO) Hedgehog F

Oral antagonist of the Hedgehog signaling component Smoothened (SMO)

Chemical name

N-(2-methyl-5-((methylamino)methyl)phenyl)-4-(4-phenylquinazolin-2-ylamino)benzamide

Parent CAS No.

[1059734-66-5]

產品資料

<button id="eiezk"><video id="eiezk"></video></button>